Friday, October 31, 2014 Last update: 7:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

IRVINE--- Endologix’s New IntuiTrak Endovascular AAA System Featured at International Congress

IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ: ELGX) today announced that a live-case demonstration of its new IntuiTrak™ Delivery System was featured at the International Congress XXII Endovascular Interventions conference in Scottsdale, Ariz. The procedure was performed by Zvonimir Krajcer, MD, Co-director of the Peripheral Vascular Disease Service at the Texas Heart Institute; Edward Diethrich, M.D., Medical Director and Founder of the Arizona Heart Institute; and Venkatesh G. Ramaiah, M.D., Vascular Surgeon at the Arizona Heart Hospital. The endovascular AAA procedure was successfully performed with a percutaneous approach and local anesthesia.

IntuiTrak is an innovative system developed for the minimally invasive delivery and deployment of the Powerlink® stent graft. The device is currently in limited market release following U.S. Food and Drug Administration approval in October 2008. IntuiTrak’s novel design and deployment mechanism simplifies standard vascular delivery of the Powerlink device and provides exceptional accuracy and control. The low-profile delivery system features enhanced flexibility, advanced hemostasis control and a hydrophilic coating to facilitate smooth delivery, particularly in patients with limited or difficult vascular access. Additionally, the delivery catheter has an integrated sheath that minimizes the need to exchange introducers, thereby having the potential to minimize vessel trauma and reduce overall procedure time.

“Due to its low-profile and integrated sheath, IntuiTrak is ideal for the percutaneous treatment of patients with AAA,” said Dr. Krajcer. “I have used the new device in eight cases so far, and have experienced 100% technical success and exceptional patient outcomes.”

“The International Congress provides an excellent opportunity to showcase IntuiTrak before a prestigious audience of physician thought-leaders in the treatment of AAA,” said John McDermott, Endologix President and CEO. “With the procedural advantages of IntuiTrak, combined with the exceptional long-term clinical results of the Powerlink device, we believe we are providing physicians with a compelling technology to treat their AAA patients. We are very encouraged by the physician feedback received to-date and are on schedule for a full-market launch in the U.S. in the second quarter of 2009.”

About International Congress

In its 22nd year, International Congress on Endovascular Interventions is a global educational forum where cardiovascular specialists gather to discuss the newest developments in endovascular interventions through peer-reviewed abstract presentations and live-case demonstrations from Arizona Heart Hospital, Arizona Heart Translational Research Center, and locations around the globe. For additional information, please visit www.endovascularcongress.org.

About Endologix

Endologix, Inc. develops and manufactures innovative therapies for aortic disorders. The company’s IntuiTrak System is an endovascular stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements relating to the introduction of new products and continuing clinical results obtained with the Powerlink System, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.